Interstitial cystitis/bladder pain syndrome: what treatments work and how successful are they?

Interstitial cystitis, now more commonly called bladder pain syndrome (IC/BPS), is a chronic condition in which pain, pressure or discomfort is perceived to arise from the bladder and is usually accompanied by urinary frequency or urgency. Symptoms commonly worsen as the bladder fills and may improve temporarily after passing urine.

IC/BPS is not the same as recurrent bacterial cystitis. Urine cultures are usually negative, antibiotics generally do not help unless a genuine infection is present, and there is no single diagnostic test or universally effective medicine.

The honest message is that IC/BPS can usually be managed, but it is rarely cured by one treatment. The most successful strategy is often a tailored combination of education, trigger management, pelvic-floor care, pain treatment and bladder-directed therapy. Treatment should be reviewed regularly and stopped if it is ineffective.

Before treatment: make sure the diagnosis fits

IC/BPS is diagnosed from the symptom pattern after excluding other important causes. Assessment may include:

A detailed history and examination
Urinalysis and urine culture
A bladder diary
Assessment for pelvic-floor tenderness
Urine cytology, imaging or cystoscopy when clinically indicated

Blood in the urine, recurrent proven infection, urinary stones, endometriosis, pelvic-floor dysfunction, overactive bladder, urethral disease and malignancy may produce overlapping symptoms.

Cystoscopy is particularly useful when Hunner lesions are suspected. These inflamed areas of the bladder lining identify an important subgroup because lesion-directed treatment is often more effective than general medication.

Urodynamic studies are not routinely required to diagnose uncomplicated IC/BPS. They may be helpful when the diagnosis is uncertain or when voiding dysfunction, obstruction or another bladder disorder is suspected.

How successful is treatment overall?

Treatment results vary considerably. Clinical trials use different diagnostic criteria and definitions of success, while IC/BPS probably represents several related conditions rather than one disease. Placebo responses can also be substantial.

For example, in a large amitriptyline trial, 55% of patients taking amitriptyline reported moderate or marked improvement, compared with 45% receiving placebo. Among patients able to tolerate at least 50 mg per day, response was 66%, compared with 47% on placebo.

This illustrates why a treatment may appear impressive in an uncontrolled case series but demonstrate only modest additional benefit in a rigorous trial.

A network meta-analysis of 23 randomised trials involving 1,871 participants found possible symptom-score benefits from amitriptyline and cyclosporine. However, no medicine consistently improved every important outcome, and none significantly reduced 24-hour urinary frequency. A more recent systematic review reached a similar conclusion: several treatments show promise, but the evidence remains limited by small trials, mixed patient populations and variable study quality.

Success should therefore be defined individually. Less pain, fewer night-time trips, longer intervals between voids, improved sexual function, better sleep or a return to normal activities may be more realistic goals than complete disappearance of symptoms.

A practical treatment ladder

1. Education, self-management and flare planning

These measures are recommended for almost everyone:

Identify individual food and drink triggers.
Avoid excessive fluid intake without deliberately becoming dehydrated.
Use heat, gentle movement, relaxation and a written flare-management plan.
Address constipation, poor sleep, anxiety, painful intercourse and associated pain conditions.
Stop smoking.
Consider gradual bladder training if it does not provoke unacceptable pain.

Frequently reported triggers include caffeine, alcohol, carbonated drinks, citrus, tomatoes, chilli and artificial sweeteners. However, triggers are highly individual and the evidence for a universal restrictive “IC diet” is weak.

A short elimination period followed by careful reintroduction is more sensible than avoiding a long list of foods indefinitely.

2. Pelvic-floor physiotherapy

Many patients with IC/BPS have a tender, overactive or poorly coordinated pelvic floor. Specialist physiotherapy may include internal and external myofascial release, muscle relaxation, breathing exercises and coordination work.

A randomised trial in women with pelvic-floor tenderness found that approximately 59% responded to myofascial physiotherapy, compared with 26% receiving general therapeutic massage.

This treatment is not simply pelvic-floor strengthening. Repetitive Kegel exercises may aggravate symptoms when the muscles are already tight and painful. Physiotherapy should ideally be provided by a pelvic-health physiotherapist familiar with IC/BPS.

3. Oral medicines

Many oral medicines used for IC/BPS are off-label in Australia. This means the medicine is prescribed for a condition or purpose not included in its Australian approval.

Off-label prescribing is common and can be appropriate, but patients should be told about the limitations in the evidence, potential adverse effects and alternative treatments.

Amitriptyline: off-label

Amitriptyline can reduce neuropathic pain, urgency and night-time symptoms and may improve sleep. It is usually started at a low dose and increased gradually according to benefit and tolerability.

Overall trial benefit has been modest, although patients who tolerated at least 50 mg per day appeared more likely to respond.

Possible adverse effects include:

Dry mouth
Constipation
Drowsiness
Weight gain
Blurred vision
Dizziness and falls
Cardiac rhythm effects

These effects may limit its usefulness, particularly in older patients.

Hydroxyzine and other antihistamines: off-label

Antihistamines are sometimes considered when allergy or mast-cell-type symptoms appear prominent. Evidence is limited and inconsistent.

Sedation, dry mouth, constipation and cognitive effects can occur. Antihistamines should not be presented as proven routine treatment for all patients with IC/BPS.

Cimetidine: off-label

Small studies suggest that cimetidine may improve pain and nocturia in some patients. However, the evidence is sparse and it is difficult to predict who will respond. Interactions with other medicines should be checked.

Pentosan polysulfate sodium: Elmiron

Pentosan polysulfate sodium, or PPS, is registered in Australia for interstitial cystitis. It is intended to supplement or protect the bladder’s glycosaminoglycan lining.

However, its efficacy has been inconsistent across clinical trials, and it should not be described as a guaranteed “bladder lining repair.” When improvement occurs, it may take several months.

The major contemporary concern is pigmentary maculopathy, a potentially serious retinal disorder associated particularly with prolonged exposure and higher cumulative doses.

The Australian Therapeutic Goods Administration advises that patients be counselled about this risk and undergo regular ophthalmic examinations, particularly during long-term treatment. New difficulty reading, blurred vision, altered colour perception or slow adjustment to dim lighting requires prompt medical and ophthalmic review.

Gabapentin, pregabalin and duloxetine: off-label

Neuropathic-pain medicines may be considered when nerve-type pain or another chronic pain syndrome coexists. Direct evidence for IC/BPS is limited.

Possible adverse effects include dizziness, drowsiness, cognitive impairment, swelling and weight gain. These medicines should be continued only when there is measurable benefit.

Opioid medicines do not treat the underlying condition and are generally avoided for long-term management because sustained benefit is uncertain and harms can accumulate.

Cyclosporine A: off-label and specialist-only

Trials suggest that cyclosporine may be more effective than pentosan polysulfate in some people with severe, refractory disease, particularly patients with Hunner lesions.

However, cyclosporine can cause:

Kidney impairment
High blood pressure
Increased infection risk
Liver abnormalities
Significant medication interactions

It is unsuitable as routine therapy. If considered, it requires careful patient selection and close monitoring of blood pressure, kidney function and other safety parameters.

4. Medicines placed directly into the bladder

Bladder instillations may be considered when oral treatments are ineffective or poorly tolerated. Catheterisation can temporarily aggravate symptoms and carries a small risk of infection or urethral trauma.

Dimethyl sulfoxide: DMSO

DMSO is an established intravesical treatment in some jurisdictions. Older trials and clinical series report response rates commonly around 50–70% in selected patients, but the studies are generally small and the certainty of this estimate is low.

Treatment may cause temporary bladder discomfort, a symptom flare, and a garlic-like taste or body odour. Availability and regulatory status vary between countries.

Heparin, lignocaine and sodium bicarbonate “rescue” instillations: off-label

Alkalinised lignocaine may provide relatively rapid, short-term pain relief. Heparin is intended to supplement the bladder’s protective surface layer.

Observational studies have reported improvement in approximately 56–73% of patients following courses of heparin-based instillations. However, controlled evidence is limited and the duration of benefit is uncertain.

These instillations may be useful during severe flares or as a monitored therapeutic trial, but they should not be described as a cure.

Hyaluronic acid and chondroitin sulphate

These bladder-coating treatments are widely used in some countries and are intended to replenish the glycosaminoglycan layer.

Some trials and observational studies report improvement, but results are inconsistent. Current comparative evidence does not reliably identify one preparation as superior.

The cost, repeated catheterisation, local availability and uncertain durability of benefit should be considered.

5. Procedures when medication is insufficient

Treatment of Hunner lesions

Fulguration, laser treatment or injection of triamcinolone into a Hunner lesion can produce substantial relief. Recurrence is common, however, and repeat treatment may be required.

This is one of the clearest reasons to identify the IC/BPS subtype rather than treating every patient identically.

Cystoscopy and hydrodistension

Low-pressure, short-duration bladder hydrodistension may help a subset of patients, usually for a limited period. Benefits are unpredictable, and symptoms may initially flare.

High-pressure or prolonged hydrodistension should be avoided because it carries greater risk without established additional benefit.

Botulinum toxin A: off-label for IC/BPS

Botulinum toxin injections into the bladder wall may reduce pain and urinary frequency in selected patients with refractory symptoms. It has sometimes been combined with hydrodistension in clinical studies.

Systematic reviews suggest possible benefit, but injection techniques, doses and study outcomes vary. Evidence for IC/BPS remains less certain than evidence supporting botulinum toxin for overactive bladder.

Risks include urinary infection, incomplete bladder emptying and the temporary need for intermittent self-catheterisation.

Neuromodulation

Posterior tibial nerve stimulation or sacral neuromodulation may be considered when urgency and frequency remain disabling.

Neither treatment reliably addresses bladder pain, and the supporting evidence specifically for IC/BPS is limited. Sacral neuromodulation involves a test phase followed by implantation of a permanent device only when the trial produces worthwhile improvement.

Major reconstructive surgery is reserved for a very small number of carefully selected patients with severe, refractory disease, particularly those with a small fibrotic bladder. Pain can persist after surgery if it is not truly bladder-centred.

Treatments that should generally be avoided

Long courses of antibiotics should not be prescribed when urine cultures do not demonstrate infection.

The American Urological Association also recommends against several historical treatments because benefit is absent or the risks outweigh it. These include:

Bacillus Calmette–Guérin treatment outside a clinical trial
Resiniferatoxin
High-pressure or prolonged hydrodistension
Long-term systemic glucocorticoids as routine IC/BPS treatment

Supplements such as quercetin, aloe vera and calcium glycerophosphate are promoted for IC/BPS, but high-quality evidence and reliable product standardisation are lacking. “Natural” does not mean risk-free, and supplements can interact with prescribed medicines.

Choosing treatment fairly

An unbiased treatment plan asks four questions:

What is the dominant problem?
Bladder-filling pain, pelvic-floor tenderness, Hunner lesions, urinary frequency and widespread pain may require different approaches.
How strong is the evidence?
Randomised controlled trials provide more reliable information than testimonials or uncontrolled case series.
What is the treatment burden?
Sedation, eye surveillance, repeated catheterisation, financial cost or the possibility of self-catheterisation may outweigh a modest benefit.
Has the treatment worked enough to continue?
Measurable goals should be agreed before treatment. Where possible, introduce one change at a time and discontinue ineffective therapy.

Combination treatment is common because IC/BPS may involve the bladder lining, sensory nerves, pelvic floor and the broader pain-processing system.

Psychological or pain-management support does not imply that symptoms are imaginary. Persistent pain can disrupt sleep, mood, relationships and nervous-system processing, and addressing these effects can improve function and quality of life.

When to seek prompt reassessment

Seek medical review for:

Visible blood in the urine
Fever or flank pain
Inability to pass urine
Recurrent positive urine cultures
Unexplained weight loss
New neurological symptoms
A significant change from the usual symptom pattern

These features should not automatically be attributed to IC/BPS.

The bottom line

There is no universally successful tablet or bladder instillation for interstitial cystitis/bladder pain syndrome.

Pelvic-floor physiotherapy has useful trial evidence in patients with pelvic-floor tenderness. Amitriptyline can help some patients who tolerate an adequate dose. Pentosan polysulfate offers uncertain average benefit and requires explicit discussion of retinal risk. Intravesical therapy, botulinum toxin and neuromodulation may help selected patients with refractory symptoms, while cyclosporine is reserved for exceptional specialist-managed cases.

Hunner lesions should be actively sought when clinically suspected because targeted treatment can be particularly valuable.

The best outcomes usually come from confirming the diagnosis, identifying the individual patient’s symptom pattern, setting realistic goals and building a treatment plan through monitored therapeutic trials, not from promising a single cure.

This article provides general information and is not a substitute for individual medical advice. Treatment availability, Australian regulatory approval and subsidy arrangements may change. Patients should discuss medications, off-label treatment, pregnancy, eye monitoring and possible drug interactions with their treating clinician.

Selected evidence and guidance

Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Journal of Urology. 2022;208:34–42. American Urological Association guideline.
European Association of Urology. EAU Guidelines on Chronic Pelvic Pain—Primary Bladder Pain Syndrome. EAU guideline.
Foster HE Jr, et al. Effect of amitriptyline on symptoms in treatment-naïve patients with interstitial cystitis/painful bladder syndrome. Journal of Urology. 2010;183:1853–1858. PubMed record.
FitzGerald MP, et al. Randomized multicenter clinical trial of myofascial physical therapy in women with IC/PBS and pelvic-floor tenderness. Journal of Urology. 2012;187:2113–2118. PubMed record.
Di X-P, et al. Efficacy and safety comparison of pharmacotherapies for IC/BPS: a systematic review and Bayesian network meta-analysis. International Urogynecology Journal. 2021;32:1129–1141. PubMed record.
Park JJ, et al. Current updates relating to treatment for IC/BPS: systematic review and network meta-analysis. BMC Urology. 2024;24:95. Open-access article.
Therapeutic Goods Administration. Pentosan polysulfate sodium—Elmiron: risk of pigmentary maculopathy. TGA safety advisory.